Abstract Radiotherapy can not only kill tumor cells directly, but also accelerate tumor regression by mediating systemic and local anti-tumor immune response. Regulatory T cells (Tregs) are known as a subset of T cells which suppress the immune system. Therefore, Tregs become one of the therapeutic targets for cancer. Recently, much attention has been paid to combination therapy with radiotherapy and anti-Tregs therapy. This article reviews the biological characteristics of Tregs and the interaction between Tregs and radiotherapy.
Ma Yuxi,Wu Gang. Research advances in the effect of regulatory T cells on tumor radiotherapy and its mechanism[J]. Chinese Journal of Radiation Oncology, 2017, 26(12): 1461-1464.
Ma Yuxi,Wu Gang. Research advances in the effect of regulatory T cells on tumor radiotherapy and its mechanism[J]. Chinese Journal of Radiation Oncology, 2017, 26(12): 1461-1464.
[1] Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Break down of a single mechanism of self-tolerance causes various autoimmune diseases[J].J Immunol,1995,155(3):1151-1164. [2] Belkaid Y, Piccirillo CA, Mendez S, et al. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity[J]. Nature,2002,420(6915):502-507.DOI:10.1038/nature01152. [3] Ohkura N, Kitagawa Y, Sakaguchi S. Development and maintenance of regulatory T cells[J]. Immunity,2013,38(3):414-423.DOI:10.1016/j.immuni.2013.03.002. [4] Bilate AM, Lafaille JJ. Induced CD4+Foxp3+ regulatory T cells in immune tolerance[J]. Annu Rev Immunol,2012,30:733-758.DOI:10.1146/annurev-immunol-020711-075043. [5] Grazia Roncarolo M, Gregori S, Battaglia M, et al. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans[J]. Immunol Rev,2006,212(1):28-50.DOI:10.1111/j.0105-2896.2006.00420.x. [6] Curiel TJ, Coukos G,Zou LH, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival[J].Nat Med,2004,10(9):942-949.DOI:10.1038/nm1093. [7] Maruyama K, Motoyama S, Anbai A, et al. Therapeutic strategy for the treatment of postoperative recurrence of esophageal squamous cell carcinoma:clinical efficacy of radiotherapy[J].Dis Esophagus,2011,24(3):166-171.DOI:10.1111/j.1442-2050.2010.01119.x. [8] Li YQ, Liu FF, Zhang XM, et al. Tumor secretion of CCL22 activates intratumoral Treg infiltration and is independent prognostic predictor of breast cancer[J].PLoS One,2013,8(10):e76379.DOI:10.1371/journal.pone.0076379. [9] Liu VC, Wong LY, Jang T, et al. Tumor evasion of the immune system by converting CD4+CD25-T cells into CD4+CD25+ T regulatory cells:role of tumor-derived TGF-β[J].J Immunol,2007,178(5):2883-2892.DOI:10.4049/jimmunol.178.5.2883. [10] Wei S, Kryczek I, Edwards RP, et al. Interleukin-2 administration alters the CD4+Foxp3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma[J]. Cancer Res,2007,67(15):7487-7494. DOI:10.1158/0008-5472.CAN-07-0565. [11] Schlecker E, Stojanovic A, Eisen C, et al. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth[J]. J Immunol,2012,189(12):5602-5611.DOI:10.4049/jimmunol.1201018. [12] Spranger S, Spaapen RM, Zha YY, et al. Up-regulation of PD-L1, IDO,and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells[J].Sci Transl Med,2013,5(200):200ra116.DOI:10.1126/scitranslmed.3006504. [13] Facciabene A, Peng XH, Hagemann IS, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells[J]. Nature,2011,475(7355):226-230.DOI:10.1038/nature10169. [14] Shang B, Liu Y, Jiang SJ, et al. Prognostic value of tumor-infiltrating Foxp3+ regulatory T cells in cancers:a systematic review and meta-analysis[J].Sci Rep,2015,5:15179.DOI:10.1038/srep15179. [15] Schmidt MA, Frtsch C, Schmidt M, et al. Circulating regulatory T cells of cancer patients receiving radiochemotherapy may be useful to individualize cancer treatment[J]. Radiother Oncol,2012,104(1):131-138. DOI:10.1016/j.radonc.2012.05.003. [16] Zitvogel L, Kroemer G. Subversion of anticancer immunosurveillance by radiotherapy[J]. Nat Immunol,2015,16(10):1005-1007.DOI:10.1038/ni.3236. [17] Anderson BE, McNiff JM, Matte C, et al. Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host disease[J]. Blood,2004,104(5):1565-1573.DOI:10.1182/blood-2004-01-0328. [18] Qu YY, Jin SG, Zhang AJ, et al. Gamma-ray resistance of regulatory CD4+CD25+Foxp3+ T cells in mice[J].Radiat Res,2010,173(2):148-157.DOI:10.1667/RR0978.1. [19] McFarland HI, Puig M, Grajkowska LT, et al. Regulatory T cells in γ irradiation-induced immune suppression[J].PLoS One,2012,7(6):e39092.DOI:10.1371/journal.pone.0039092. [20] Li CG, Wu FL, Li YJ, et al. Akt promotes irradiation-induced regulatory T-cell survival in hepatocellular carcinoma[J]. Am J Med Sci,2013,346(2):123-127. DOI:10.1097/MAJ.0b013e31826ceed0. [21] Balogh A, Persa E, Bogdándi EN, et al. The effect of ionizing radiation on the homeostasis and functional integrity of murine splenic regulatory T cells[J]. Inflamm Res,2013,62(2):201-212. DOI:10.1007/s00011-012-0567-y. [22] Baria K, Warren C, Roberts SA, et al. Chromosomal radiosensitivity as a marker of predisposition to common cancers?[J]. Br J Cancer,2001,84(7):892-896.DOI:10.1054/bjoc.2000.1701. [23] Cao MD, Cabrera R, Xu YL, et al. Gamma irradiation alters the phenotype and function of CD4+CD25+ regulatory T cells[J].Cell Biol Int,2009,33(5):565-571.DOI:10.1016/j.cellbi.2009.02.007. [24] Liu S, Sun XD, Luo JH, et al. Effects of radiation on T regulatory cells in normal states and cancer:mechanisms and clinical implications[J]. Am J Cancer Res,2015,5(11):3276-3285. [25] Battaglia A, Buzzonetti A, Martinelli E, et al. Selective changes in the immune profile of tumor-draining lymph nodes after different neoadjuvant chemoradiation regimens for locally advanced cervical cancer[J]. Int J Radiat Oncol Biol Phys,2010,76(5):1546-1553.DOI:10.1016/j.ijrobp.2009.10.014. [26] Liao C, Xiao W, Zhu N, et al. Radiotherapy suppressed tumor-specific recruitment of regulator T cells via up-regulating microR-545 in Lewis lung carcinoma cells[J]. Int J Clin Exp Pathol,2015,8(3):2535-2544. [27] Fadul CE, Fisher JL, Gui J, et al. Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme[J]. Neuro Oncol,2011,13(4):393-400. DOI:10.1093/neuonc/noq204. [28] Lissoni P, Brivio F, Fumagalli L, et al. Effects of the conventional antitumor therapies surgery, chemotherapy, radiotherapy and immunotherapy on regulatory T lymphocytes in cancer patients[J]. Anticancer Res,2009,29(5):1847-1852. [29] 高俊峰,汪毅,鲍健,等.肺癌骨转移患者放疗前后HSP70水平和Treg比例变化及其与疗效的关系[J].临床肺科杂志,2016,21(8):1463-1466.DOI:10.3969/j.issn.1009-6663.2016.08.031. Gao JF, Wang Y, Bao J, et al. Changes of HSP70 level and Treg ratio before and after radiotherapy in patients with bone metastasis of lung cancer and their relationship with curative effect[J]. J Clin Pulmonary Med,2016,21(8):1463-1466. DOI:10.3969/j.issn.1009-6663.2016.08.031. [30] Kachikwu EL, Iwamoto KS, Liao YP, et al. Radiation enhances regulatory T cell representation[J]. Int J Radiat Oncol Biol Phys,2011,81(4):1128-1135. DOI:10.1016/j.ijrobp.2010.09.034. [31] Le DT, Jaffee EM. Regulatory T-cell modulation using cyclophosphamide in vaccine approaches:a current perspective[J]. Cancer Res,2012,72(14):3439-3444.DOI:10.1158/0008-5472.CAN-11-3912. [32] Popp I, Grosu AL, Niedermann G, et al. Immune modulation by hypofractionated stereotactic radiation therapy:therapeutic implications[J]. Radiother Oncol,2016,120(2):185-194.DOI:10.1016/j.radonc.2016.07.013. [33] Patel M,Kim J,Theodros D,et al. Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma[J].J Immunother Cancer,2015,3(S2):194.DOI:10.1186/2051-1426-3-S2-P194. [34] Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function[J]. Science,2008,322(5899):271-275.DOI:10.1126/science.1160062. [35] Young KH, Baird JR, Savage T, et al. Optimizing timing of immunotherapy improves control of tumors by hypofractionated radiation therapy[J]. PLoS One,2016,11(6):e0157164. DOI:10.1371/journal.pone.0157164. [36] Zheng ZM, Wang P, Wang HY, et al. Combining heavy ion radiation and artificial microRNAs to target the homologous recombination repair gene efficiently kills human tumor cells[J]. Int J Radiat Oncol Biol Phys,2013,85(2):466-471.DOI:10.1016/j.ijrobp.2012.04.008. [37] Twyman-Saint Victor C, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer[J]. Nature,2015,520(7547):373-377.DOI:10.1038/nature14292. [38] Lipson EJ. Re-orienting the immune system:durable tumor regression and successful re-induction therapy using anti-PD1 antibodies[J]. Oncoimmunology,2013,2(4):e23661. DOI:10.4161/onci.23661.
2017, Vol. 26 
